IM Cannabis (IMCC) Intangibles (2019 - 2026)

IM Cannabis (IMCC) posted quarterly Intangibles of $562946.8 for Q1 2026, down 35.76% quarter-over-quarter from $876279.4 in Q4 2025.

IM Cannabis (IMCC) Intangibles (2019 - 2026) Analysis & Trends

IM Cannabis' Intangibles history runs 8 years deep, the most recent figure standing at $562946.8 for Q1 2026.

In Q1 2026, Intangibles changed N/A year-over-year to $562946.8; the TTM figure through Mar 2026 stood at $562946.8 (changed N/A YoY), while the FY2025 annual figure was $876279.4, down 64.0% from the prior year.
Intangibles for Q1 2026 stood at $562946.8, down from $876279.4 in the prior quarter.
The five-year high for Intangibles was $23.2 million in Q1 2022, with the low at $562946.8 in Q1 2026.
The 5-year median for Intangibles is $4.1 million (2023), against an average of $5.6 million.
The sharpest annual moves came in 2022 and 2023: Intangibles surged 294.11% in 2022, then tumbled 76.65% in 2023.
IM Cannabis' Intangibles stood at $5.8 million in 2022, then decreased by 26.85% to $4.3 million in 2023, then tumbled by 44.03% to $2.4 million in 2024, then tumbled by 63.27% to $876279.4 in 2025, then plunged by 35.76% to $562946.8 in 2026.
Business Quant data shows IMCC's Intangibles at $562946.8 in Q1 2026, $876279.4 in Q4 2025, and $1.2 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Intangibles (Qtr)
1	Haleon	43.83 Bn	42.86 Bn	-	-
2	Teva Pharmaceutical Industries	42.87 Bn	39.22 Bn	2.15 Bn	3.45 Bn
3	Zoetis	31.41 Bn	29.73 Bn	1.05 Bn	918.00 Mn
4	Takeda Pharmaceutical	28.55 Bn	22.75 Bn	5.10 Bn	21.28 Bn
5	United Therapeutics	22.08 Bn	19.42 Bn	683.80 Mn	-
6	Viatris	18.73 Bn	17.84 Bn	1.46 Bn	13.68 Bn
7	Neurocrine Biosciences	15.44 Bn	15.05 Bn	935.80 Mn	2.23 Bn
8	Elanco Animal Health	11.75 Bn	11.22 Bn	798.00 Mn	3.20 Bn
9	Dr Reddys Laboratories	10.11 Bn	9.94 Bn	-	1.12 Bn
10	IM Cannabis	554,496.00	-614,474.17	1.09 Mn	331,099.78

Download Data